Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus

Australian Veterinary Journal

Volumn 80, Issue 1-2, 2002, Pages 61-66

  Karpathy, R C ^a   Firth, G A ^a   Tannock, G A ^b  

^a Vaccine Production Laboratory   (Australia)

^b RMIT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; VIRUS VACCINE;

ANIMAL; ARTICLE; AVIAN LYMPHOMATOSIS HERPETOVIRUS; BIRD DISEASE; CHICKEN; EVALUATION; GERMFREE ANIMAL; IMMUNOLOGY; PATHOGENICITY; VIRUS;

ANIMALS; CHICKENS; DRUGS, INVESTIGATIONAL; HERPESVIRUS 2, GALLID; MAREK DISEASE; SPECIFIC PATHOGEN-FREE ORGANISMS; VIRAL VACCINES; VIRUSES;

EID: 0036047234     PISSN: 00050423     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-0813.2002.tb12838.x     Document Type: Article

References (23)

1. McKimm-Breschkin JL, Faragher JT, Withell J, Forsyth WM. Isolation of very virulent Marek's disease viruses from vaccinated chickens in Australia. Aust Vet J 1990;67:205-209.
2. Jackson CAW. Failure of imported genetic strains of layer chickens to respond to Australian-derived Marek's disease vaccines In. Proceedings of the 5th International Symposium on Marek's Disease, American Association of Avian Pathologists, 1996.
3. Witter RL. Attenuated revenant serotype 1 Marek's disease viruses: safety and protective efficacy. Avian Dis 1991;35:877-891.
4. Sarma G, Greer W, Gildersleeve RP, Murray DL, Miles AM. Field safety and efficacy of in ovo administration of HVT + SB-1 bivalent Marek's disease vaccine in commercial broilers. Avian Dis 1995, 39: 211-217.
5. Kross I. Isolation of highly lytic serotype 1 Marek's disease viruses from recent field outbreaks in Europe. In: Proceedings of the 5th International Symposium on Marek's Disease, American Association of Avian Pathologists, 1996.
6. Venugopal K, Bland AP, Ross LNJ, Payne LN Pathogenicity of an unusual highly virulent Marek's disease virus isolated in the United Kingdom. In: Proceedings of the 5th International Symposium on Marek's Disease, American Association of Avian Pathologists, 1996.
7. Rispens BH, van Volten HJ, Mastenbroek N, Maas HJL, Schat KA. Control of Marek's disease in The Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian Dis 1972;16:108-125
8. Rispens BH, van Volten HJ, Mastenbroek N, Maas HJL. Control of Marek's disease in The Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek's disease virus. Avian Dis 1972;16:126-138.
9. Lee LF, Liu X, Witter RL Monoclonal antibodies with specificity for three different serotypes of Marek's disease virus in chickens. J Immunol 1983;130:1003-1006.
10. Zerbes M, Tannock GA, Jenner RJ, Young PL. Some characteristics of a recent virulent isolate of Marek's disease virus. Aust Vet J 1994;71:21-22.
11. De Laney DB, Morrow CJ, Read KM, Tannock GA. The development and evaluation of two tissue culture-grown Marek's disease challenge viruses. Avian Pathol 1998;27:472-477.
12. Anonymous. Marek's disease vaccine (live). In: European Pharmacopoeia. 3rd edn. Council of Europe, Strasbourg, 1997.1144-1146.
13. Churchill AE, Chubb RC, Baxendale W. The attenuation, with loss of oncogenicity, of the herpes-type virus of Marek's disease (strain HPRS-16) on passage in cell culture. J Gen Virol 1969;4:5S7-564.
14. Calnek BW, Harris RW, Buscaglia C, Schat KA, Lucio B. Relationship between the immunosuppressive potential and the pathotype of Marek's disease isolates. Avian Dis 1998,42:124-132.
15. Witter RL Increased virulence of Marek's disease virus field isolates. Avian Dis 1997;41:149-163.
16. Witter RL. New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: Comparative efficacy. Avian Dis 1987;31:752-765.
17. Witter RL, Lee LF, Fadly AM. Characteristics of CVI988/ Rispens and R2/23, two prototype vaccine strains of serotype 1 Marek's disease virus. Avian Dis 1995;39:269-284.
18. Witter RL, Lee LF. Polyvalent Marek's disease vaccines: safety, efficacy and protective synergism in chickens with maternal antibodies. Avian Pathol 1984;13.75-92.
19. De Laney DB. The development of a serotype 1 vaccine against Marek's disease [Ph D thesis] RMIT University, Victona, 1999.
20. Bülow Vv. Further characterisation of the CVI 988 strain of Marek's disease virus. Avian Pathol 1977;6:395-403.
21. Witter RL. Influence of serotype and virus strain on synergism between Marek's disease vaccine viruses. Avian Pathol 1992;21:601-614.
22. 65 clone C against challenge infection with three very virulent MDV strains. Avian Dis 1986;30:276-283.
23. Sarma G, Greer W, Estep C, Winkler DC Field trial and immunogenicity studies on the polyvalent Marek's disease vaccines in chickens. In: Proceedings of the 4th International Symposium on Marek's Disease, Amsterdam, 1992.